Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly
The bare-knuckle brawl between Vertex’s executive crew and NICE has now extended to its new cystic fibrosis combo Symkevi — matching tezacaftor and ivacaftor.
Late last week the British drug price regulator put out word that it was halting its appraisal of Symkevi — sold in the US as Symdeko — because Vertex “has not provided an evidence submission for this appraisal.”
A meeting planned for November 8, as a result, has been cancelled.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.